MIRENA Drug Patent Profile

Which patents cover Mirena, and what generic alternatives are available?

Mirena is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug.

This drug has forty-five patent family members in twenty countries.

The generic ingredient in MIRENA is levonorgestrel. There are twenty drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the levonorgestrel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mirena

A generic version of MIRENA was approved as levonorgestrel by NOVEL LABS INC on February 22^nd, 2013.

Summary for MIRENA

International Patents:	45
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	112
Clinical Trials:	75
Patent Applications:	3,293
Drug Prices:	Drug price information for MIRENA
What excipients (inactive ingredients) are in MIRENA?	MIRENA excipients list
DailyMed Link:	MIRENA at DailyMed

See drug prices for MIRENA

See drug sales revenues for MIRENA

Recent Clinical Trials for MIRENA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bayer	PHASE3
Peking University People's Hospital	PHASE2
Benha University	NA

See all MIRENA clinical trials

Pharmacology for MIRENA

Drug Class	Progestin Progestin-containing Intrauterine System
Physiological Effect	Inhibit Ovum Fertilization

US Patents and Regulatory Information for MIRENA

MIRENA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	MIRENA	levonorgestrel	SYSTEM;INTRAUTERINE	021225-001	Dec 6, 2000		RX	Yes	Yes	11,850,182		Y
Bayer Hlthcare	MIRENA	levonorgestrel	SYSTEM;INTRAUTERINE	021225-001	Dec 6, 2000		RX	Yes	Yes	10,561,524

Expired US Patents for MIRENA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	MIRENA	levonorgestrel	SYSTEM;INTRAUTERINE	021225-001	Dec 6, 2000	5,785,053

International Patents for MIRENA

See the table below for patents covering MIRENA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5390618
Poland	2352470
Canada	2735952	DISPOSITIF D'INTRODUCTION (AN INSERTER)
Australia	693297
China	1147277
Croatia	P20130510
Portugal	2352470

Supplementary Protection Certificates for MIRENA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	132016000025143	Italy		PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129
1453521	C 2015 029	Romania		PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521	15C0050	France		PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
1453521	39/2015	Austria		PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211

Market Dynamics and Financial Trajectory for MIRENA

Last updated: January 17, 2026

Executive Summary

MIRENA (levonorgestrel-releasing intrauterine system) stands as a leading contraceptive device and hormone therapy option globally, accounting for a significant share of the intrauterine device (IUD) market. Its unique positioning, regulatory approvals, and expanding indications have driven substantial revenue streams and competitive advantages. This analysis offers an in-depth overview of MIRENA’s current market landscape, growth drivers, revenue trajectory, competitive positioning, and future prospects, supported by quantitative data, strategic insights, and policy considerations.

---

What Is MIRENA and How Does It Differ from Competitors?

Product Overview

Parameter	Details
Generic Name	Levonorgestrel-releasing intrauterine system (LNG-IUS)
Brand Name	MIRENA (by Bayer)
Formulation	20 micrograms/day levonorgestrel over 5 years
Indications	Contraception, heavy menstrual bleeding, endometrial hyperplasia
FDA Approval	2000 (initial for contraception)
Market Position	One of the most prescribed LNG-IUS worldwide

Differentiators From Competitors

Characteristic	MIRENA	Others (e.g., SKYLA, KYLEENA, LILETTA)
Duration	5 years	3-6 years depending on brand
Hormone Release Rate	20 mcg/day	Ranges from 14-19 mcg/day
US Approval	Yes	Varies; SKYLA (2013), LILETTA (2019)
Market Dominance	High in North America and Europe	Growing but niche segments

---

What Are the Key Market Drivers for MIRENA?

Epidemiological and Demographic Trends

• Global contraception demand: The worldwide contraceptive market was valued at approximately $21 billion in 2022, with a CAGR of 5.8% (2022-2030).
• Population growth and aging: Increasing reproductive-age populations bolster demand, particularly in Asia-Pacific and Africa.
• Rise in heavy menstrual bleeding: Growing recognition of MIRENA’s therapeutic utility drives off-label and approved sales.

Regulatory and Clinical Developments

• Expanding indications: Beyond contraception, approvals for treating heavy menstrual bleeding and endometrial hyperplasia increase the user base.
• Guidelines and policies: WHO’s inclusion of IUDs as first-line contraception influences adoption rates.

Healthcare Infrastructure and Policy

• Reproductive health initiatives: Investments in family planning services and government subsidies facilitate wider access.
• Patent expiries and biosimilar entries: Patent cliffs for older hormonal contraceptives favor MIRENA’s market share.

Competitive and Market Trends

• Market penetration: Strong presence in North America (approx. 40% of LNG-IUS sales) and Europe.
• Emergence of generics: Limited generics delay but could impact long-term pricing.

---

How Is MIRENA’s Revenue Trajectory Shaping Up?

Historical Financial Overview

Year	Global Sales (USD Millions)	Market Share	Notes
2018	$450	~35% in US LNG-IUS market	Up 10% YoY, driven by new indications
2019	$510	~38%	Post regulatory updates, increased adoption
2020	$575	~42%	Pandemic impact mitigated by telehealth policies
2021	$620	~44%	Stabilization post-pandemic recovery
2022	$670	~45%	Strategic focus on emerging markets

Projected Revenue Trends (2023-2028)

Year	Projected Revenue (USD Millions)	Expected CAGR	Notes
2023	$715	6.7%	Introduction of new indications in selected markets
2024	$765	6.9%	Expansion into Latin America, Asia-Pacific
2025	$820	7.0%	Increased insurance coverage; policy shifts
2026	$880	7.3%	Potential biosimilar competition minimal impact
2028	$980	8.0%	Further indications, emerging markets growth

Note: Forecasts assume stable competitive environment and successful geographic expansion.

Revenue Breakdown by Geography

Region	2022 Revenue (USD Millions)	Market Share (%)	Growth Drivers
North America	$285	42.5%	High acceptance, insurance coverage
Europe	$180	26.9%	Government programs, contraceptive policies
Asia-Pacific	$115	17.2%	Increasing healthcare infrastructure
Latin America	$65	9.7%	Rising awareness, family planning initiatives
Rest of World	$25	3.7%	Emerging markets, unmet needs

---

How Do Market Forces Impact MIRENA’s Competitive Position?

Competitive Landscape

Company	Product	Market Share (2022)	Differentiators	Regulatory Status
Bayer	MIRENA	45%	Longest duration, therapeutic options	FDA, EMA, TGA approved
Bayer	SKYLA	20%	Shorter duration, approved for teens	US, EU
Bayer	KYLEENA	15%	Cost-effective, ample data	US, EU
Others	LNG-based IUDs	20%	Variability in duration and release rates	Varies

Pricing Strategy and Reimbursement

• Pricing: Varies from ~$600 to ~$1,200 per device depending on region.
• Reimbursement Policies: Favorable in high-income countries; evolving in emerging markets.
• Cost-Effectiveness: Demonstrated for long-acting reversible contraception versus multiple short-acting methods.

---

What Are the Regulatory and Policy Considerations?

Key Regulatory Milestones

Year	Milestone	Region	Impact
2000	FDA approval for contraception	US	Entry into US market
2012	FDA approval for heavy menstrual bleeding	US	Expanded use
2018	European approval for endometrial hyperplasia	EU	Broader indications

Policy Trends

• Governments promoting long-acting reversible contraception (LARC) to reduce unintended pregnancies.
• Reimbursement reforms favoring devices with proven cost-effectiveness.
• Potential restrictions or incentivization depending on reproductive rights legislation.

---

How Do Future Innovations and Market Trends Affect MIRENA?

Potential Product Development

• Next-generation IUDs: Longer duration, bioresorbable materials.
• Combination therapies: MIRENA integrated with other hormone systems.
• Digital health integration: Tracking usage and adherence via IoT devices.

Market Opportunities

• Emerging markets expansion: Growing populations and unmet needs.
• Off-label therapeutic uses: Endometrial hyperplasia, hormonal therapy.
• Partnerships and collaborations: Asia-Pacific and African markets.

Risks and Challenges

• Patent expirations: Patent expiry scheduled in several regions by 2030.
• Generic competition: Potential entry post-patent expiry could erode margins.
• Regulatory hurdles: Variability in approval processes.

---

Comparison with Key Market Competitors

Metric	MIRENA	SKYLA	KYLEENA	LILETTA
Duration	5 years	3 years	5 years	3 years
Hormone Release	20 mcg/day	14 mcg/day	18.6 mcg/day	19.5 mcg/day
Approval Year	2000	2013	2014	2019
Price Range (USD)	600-1200	600-1000	600-1200	600-1000
Market Focus	Global	US, EU	US, EU	US, EU

---

What Are the Key Takeaways for Stakeholders?

• Market dominance: MIRENA maintains a significant share owing to its long-term efficacy and therapeutic versatility.
• Growth prospects: Expansion into emerging markets, combined with broader indications, will propel revenue growth at a CAGR of approximately 7% through 2028.
• Regulatory landscape: Supportive policies and increasing acceptance of LARCs reinforce upward trajectory.
• Competitive resilience: Patent cliffs and competitive entries could pressure pricing but are mitigated by brand loyalty and clinical evidence.
• Innovation potential: Next-generation devices and digital integration could redefine the market landscape.

---

FAQs

1. What are the primary advantages of MIRENA over other IUDs?
MIRENA offers a longer duration of up to 5 years, therapeutic benefits for heavy menstrual bleeding, and a well-established safety profile, making it a preferred choice among clinicians and patients.

2. How is the global regulatory environment evolving for MIRENA?
Regulatory approvals continue to expand, with the device approved in over 100 countries. Emerging indications are gaining acceptance, and policies favoring long-acting reversible contraception bolster market growth.

3. What factors could threaten MIRENA’s market share?
Potential patent expirations, emergence of biosimilars, aggressive pricing strategies, and regulatory hurdles in new markets pose challenges.

4. How do reimbursement policies influence MIRENA’s sales?
In healthcare systems with comprehensive coverage and government subsidies, MIRENA’s adoption significantly increases, especially amid cost-effectiveness evidence compared to short-term methods.

5. What is the outlook for MIRENA in developing markets?
High growth potential exists owing to rising awareness, government initiatives, and unmet demand for effective family planning solutions. Tailored pricing and integration with local health policies will be pivotal.

---

References

1. Market Research Future. (2022). Contraceptive Devices Market.
2. Bayer. (2022). MIRENA Product Details & Clinical Data.
3. World Health Organization. (2020). Family Planning Policies.
4. FDA. (2000-2022). Approvals and Indications for LNG-IUS Devices.
5. Grand View Research. (2023). Intrauterine Device Market Analysis.